Study of Blarcamesine in a New Parkinson’s Model of Combined Alpha-Synuclein Pathology and Noradrenergic Dysfunction

Anavex Life Sciences Corp. published this content on March 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 17, 2026 at 11:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]